Biopharmaceutical company with technology and IP licensed from Stanford University, developing a protein therapy for epidermolysis bullosa (EB), a rare genetic skin disease
Nova Anchora
Recent Posts
Recent Comments
No comments to show.
Biopharmaceutical company with technology and IP licensed from Stanford University, developing a protein therapy for epidermolysis bullosa (EB), a rare genetic skin disease